Supplementary Table 4. Characteristics of included studies for HbA1c reduction efficacy of antidiabetic treatments after 6 months

Treatment	Number of studies	Number of subjects	Mean baseline HbA1c
Placebo	31	2,844	7.9
Met	22	3,486	7.6
SU	8	1,743	7.6
TZD	11	2,225	7.6
DPP4i	24	3,531	7.9
SGLT2i	9	1,992	8.0
GLP-1RA	9	2,590	8.0
Met+SU	2	49	7.9
Met+TZD	3	207	7.6
Met+DPP4i	6	591	7.8
Met+SGLT2i	3	179	7.9
Met+GLP-1RA	1	84	8.0
DPP4i+TZD	1	371	8.1
DPP4i+SGLT2i	1	269	8.0
Total	58	20,161	7.8

HbA1c, glycosylated hemoglobin; Met, metformin; SU, sulfonylurea; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist.